Drug margin is the business. Everything else moves around it.
In community oncology, a few points of drug margin can outweigh a whole quarter of visit growth. Acquisition cost, ASP lag, biosimilar substitution, payer coverage, and infusion chair utilization decide whether the practice funds itself. Our monthly briefing reads those lines together with the standard revenue cycle so you can see which part of the business is actually carrying the practice.
Where the specialty stands
Heme/Onc economics live and die on drug margin, the 340B program, and access to clinical trials. Community oncology faces ongoing site-of-service pressure from health systems, while biosimilar adoption and the Inflation Reduction Act's drug pricing provisions are reshaping the buy-and-bill model in real time.
- IRA-driven Medicare price negotiation and Part B inflation rebates are starting to show up in real margin compression on selected drugs.
- Biosimilars (oncology supportive care and increasingly therapeutics) keep eroding ASP-based revenue but improve access.
- Community oncology consolidation (OneOncology, USON, AON) continues; staying independent requires real ancillary depth.
- Oral oncology drugs shift revenue from medical to pharmacy benefits. An in-house specialty pharmacy is a strategic decision, not just an operating detail.
- Clinical trial participation is a recruitment, branding, and revenue engine that smaller groups can punch above their weight on.
What the briefing reads for a hematology / oncology practice
Acquisition cost against reimbursement by regimen, the spread on high-volume agents, ASP repricing lag, and how biosimilar substitution shifts revenue and margin from one quarter to the next.
Chair hours used against chair hours available, treatment-day clustering, and the gap between scheduled and delivered treatments. Idle chair time is fixed cost that never comes back.
Prior authorization turnaround, denial rate by payer and regimen, and the share of write-offs that trace back to authorization rather than coding. In heme/onc a single denied cycle is a large dollar event.
Days in A/R and aging buckets tracked by payer, plus how much of the aged balance sits in high-cost drug claims. Slow payment on drug claims is a cash-flow problem before it is a margin problem.
Staff per provider is structurally higher here: nursing, pharmacy, authorization, financial navigation, and triage. We watch labor cost against treatment volume rather than against visit counts.
Lab, pathology, imaging, oral oncology, in-house dispensing, and trial participation. These lines often decide whether an independent group can keep recruiting and reinvesting.
Illustrative reference ranges
Read the methodologyThese internally authored, industry-informed estimates provide specialty context. They are not live peer data, licensed survey medians, targets, or promises.
| Indicator | Lower reference | Central reference | Upper reference |
|---|---|---|---|
| Revenue per provider (monthly) | $95k | $120k | $150k |
| Days in A/R | 34 days | 42 days | 52 days |
| Net collection rate | 94% | 96.5% | 98.2% |
| Contractual adjustment rate | 22% | 28% | 34% |
| Average reimbursement rate | 66% | 74% | 82% |
| Staff per provider | 3.8 | 4.5 | 5.2 |
| Commercial payer mix | 48% | 60% | 72% |
| Third next available appointment | 2 days | 5 days | 9 days |
| No-show rate | 3.5% | 5.5% | 7.5% |
| Scheduling efficiency | 76% | 84% | 90% |
| Provider turnover | 3% | 6% | 9% |
| Training investment (% of payroll) | 1.6% | 2.4% | 3.2% |
| Operating expense ratio | 64% | 70% | 76% |
| Cost per visit | $290 | $360 | $430 |
| Patient satisfaction | 4.3 / 5 | 4.6 / 5 | 4.8 / 5 |
| Quality compliance rate | 90% | 94% | 97% |
Questions this briefing is built to answer
- Is our drug margin holding, and which regimens are pulling it down?
- Are infusion chairs the constraint, or is the schedule leaving capacity unused?
- How much revenue is sitting in aged A/R on high-cost drug claims?
- Is our authorization workflow keeping pace with treatment volume?
- Are oral oncology shifts moving revenue off the medical benefit faster than we planned?
- Is staffing cost growing faster than treatment volume, and where?
- What would a payer policy change on a top regimen do to next quarter's cash?
- Are we financially strong enough to stay independent through the next contract cycle?
What we read to stay current
See what this looks like for your practice
Send aggregate practice data for a recent period and we will show you the executive brief format: what changed, why it may matter, likely drivers, and what to watch.
AileronMD analyzes business, financial, and operational data only. Do not submit patient records or protected health information. AileronMD does not provide clinical or medical advice, and does not guarantee financial results. Guidance is advisory; practice leadership makes the decisions.